Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 2:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 43 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vasopressin, Arginine Clear all
Completed Phase 3 Interventional Results available

Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients

NCT01262456
View directory record Official record
Conditions
Nocturia
Interventions
Desmopressin, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
51
States / cities
Anniston, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 1, 2026, 2:27 PM EDT
Recruiting Early Phase 1 Interventional

Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease

NCT07568509
View directory record Official record
Conditions
Arginine Vasopressin Deficiency, Oxytocin Deficiency, Pediatric Disease, Hypopituitarism
Interventions
Norethindrone Acetate-Ethinyl Estradiol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Vasopressin and Pain Perception in the Brain

NCT03446456
View directory record Official record
Conditions
Acute Pain
Interventions
Arginine vasopressin, Saline, Observational learning, fMRI data aquisition
Drug · Other · Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

V2 Receptor Effects on Fluid Regulation and Performance

NCT02084797
View directory record Official record
Conditions
Electrolyte Imbalance, Hyponatremia, Hypernatremia
Interventions
V2R (Vasopressin 2 receptor)
Drug
Lead sponsor
Oakland University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Michigan
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 1, 2026, 2:27 PM EDT
Terminated No phase listed Observational

Vasopressin Hemodynamic Response as a Septic Shock Subphenotype Indicator

NCT06426407
View directory record Official record
Conditions
Shock, Septic
Interventions
Vasopressin
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Not applicable Interventional

Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction

NCT00816127
View directory record Official record
Conditions
Liver Cirrhosis, Coagulopathy
Interventions
Desmopressin, blood transfusion
Drug · Biological
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2009 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Phase 2 Interventional

Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration

NCT05190744
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease, Nephrogenic Diabetes Insipidus, Acquired Nephrogenic Diabetes Insipidus, Congenital Nephrogenic Diabetes Insipidus
Interventions
PB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

To Evaluate the Renal Tubular Function Pre and Post Nephrectomy in Living Donors

NCT03676361
View directory record Official record
Conditions
Kidney Damage
Interventions
Desmopressin
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Oct 1, 2026, 2:27 PM EDT
Completed No phase listed Observational

Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus

NCT00004363
View directory record Official record
Conditions
Diabetes Insipidus, Diabetes Insipidus, Neurohypophyseal
Interventions
chlorpropamide, desmopressin
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
6 Months to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 1, 2026, 2:27 PM EDT
Terminated No phase listed Observational

Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease

NCT02636387
View directory record Official record
Conditions
Nocturnal Enuresis, Anemia, Sickle Cell
Interventions
Desmopressin
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
8 Years to 21 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Early Use of Vasopressin in Post-Fontan Management

NCT03088345
View directory record Official record
Conditions
Circulatory Perfusion Disorder, Congenital Heart Disease, Single-ventricle
Interventions
Vasopressin, Arginine, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Weeks to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Not applicable Interventional Results available

Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients

NCT00795366
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
arginine vasopressin, Standard catecholamine
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2014 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vasopressin Effects on Human Social Communication

NCT01327027
View directory record Official record
Conditions
Healthy
Interventions
Vasopressin, Arginine, ADH, Placebo; Sterile Saline
Drug
Lead sponsor
Bowdoin College
Other
Eligibility
18 Years to 30 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Phase 1 Interventional

Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers

NCT02506023
View directory record Official record
Conditions
Hemophilia A
Interventions
Desmopressin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Oct 1, 2026, 2:27 PM EDT
Terminated Not applicable Interventional

Optimizing the Social Engagement System in Prader-Willi Syndrome: Insights From the Polyvagal Theory

NCT03101826
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Listening Project Protocol
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
13 Years to 25 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Brewster, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 1, 2026, 2:27 PM EDT
Withdrawn Phase 4 Interventional

Angiotensin II vs. Vasopressin in Septic Shock

NCT05193370
View directory record Official record
Conditions
Septic Shock
Interventions
Angiotensin II, Vasopressin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 1, 2026, 2:27 PM EDT
Enrolling by invitation No phase listed Observational

International Multi-center Retrospective Study of Patients With Serum Sodium ≤110 mmol/L to Determine the Relationship Between Osmotic Demyelination Syndrome (ODS) and Rapid Correction of Hyponatremia

NCT07576036
View directory record Official record
Conditions
Hyponatremia Symptomatic, Osmotic Demyelination Syndrome, Cerebral Edema
Interventions
Hypertonic 3% saline
Drug
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock

NCT01611935
View directory record Official record
Conditions
Traumatic Shock
Interventions
Vasopressin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Not applicable Interventional Results available

Study of Dopamine Versus Vasopressin for Treatment of Low Blood Pressure in Low Birth Weight Infants

NCT01318278
View directory record Official record
Conditions
Hypotension
Interventions
Dopamine, Arginine Vasopressin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 24 Hours
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 1, 2026, 2:27 PM EDT